Business
Comment on the COVID-19 vaccine announcement
Comment on the COVID-19 vaccine announcement.
About this update from Theracryf Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8922E\n Evgen Pharma PLC\n 11 November 2020\n \n \n \n \n Evgen Pharma plc\n \n \n \n \n \n (\"Evgen\" or the \"Company\")\n \n \n \n \n \n Comment on COVID-19 vaccine announcement\n \n \n \n \n \n Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, notes the recent news that Pfizer have announced the first interim analysis of a Phase III COVID-19 vaccine. Evgen believe that multiple approaches will be needed to curtail this virus and the progress announced earlier this week is a hugely positive development. \n \n \n \n \n \n As previously announced, Evgen have entered into a Phase II/III trial with the University of Dundee to investigate whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome (\"ARDS\") including, but not exclusively in patients with suspected COVID-19. The Company confirms that this study is poised to commence recruitment, as announced on 23 October 2020 and will be providing a further update shortly.\n \n \n \n \n \n The Phase II/III STAR trial (SFX-01 Treatment for Acute Respiratory Infections) has received all the necessary regulatory approvals needed to proceed and patient recruitment will begin shortly. Supplies of SFX-01 have already been delivered to the centre.\n \n \n \n \n \n \n Dr Huw Jones, Evgen CEO, commented:\n \n \n \"We are pleased to see such progress on a potential vaccine against COVID-19. Recently ARDS has been heavily associated with COVID-19 as it affects the respiratory tract, but it is and will remain a condition in its own right long after we have beaten the pandemic and will continue to be a huge problem for patients. There is a considerable unmet need for effective treatments for ARDS and the outcome of our study will hopefully show how we can use SFX-01 in a serious respiratory condition regardless of the infective agent involved.\"\n \n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n Evgen Pharma\n \n \n plc\n \n \n \n www.evgen.com\n \n \n \n \n \n \n \n \n via Walbrook\n \n \n \n \n \n \n \n \n Barry Clare, Chairman\n \n \n Dr Huw Jones, CEO \n \n \n \n \n \n \n \n \n \n \n \n \n \n Richard Moulson, CFO \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n fi...